FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates (Gore) today announced that it has received approval to apply the CE Mark and commence commercial distribution of its GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface in the European Union. The GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface combines Gore’s propriety heparin surface with the proven performance of the GORE VIABAHN Endoprosthesis for the treatment of arterial vascular disease. The GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface is indicated for the endovascular grafting of peripheral arteries.
The GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface uses end-point covalent bonding to keep the heparin anchored to the endoprosthesis surface over time. The proprietary end-point surface attachment technology preserves the heparin bioactive sites such that they remain free to interact with the blood without being consumed.
“Gore is excited to provide the clinical community in Europe with the same proven heparin bonded surface technology for patients suffering from peripheral arterial vascular disease that clinicians in the US have been using to treat occlusive disease in the Superficial Femoral Artery for the past 18 months,” said Ben Beckstead, PhD, Product Specialist with the Gore Peripheral Vascular Business.
GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface (5 to 8 mm devices) is available with a low-profile delivery system that gives interventionalists a more streamlined approach to re-line the peripheral arteries. The GORE VIABAHN Endoprosthesis is constructed with a durable, reinforced, biocompatible, ePTFE liner attached to an external nitinol stent structure. The excellent flexibility of the GORE VIABAHN Endoprosthesis enables it to better traverse tortuous areas of the Superficial Femoral Artery and conform more closely to the complex anatomy of the artery.
ABOUT W. L. GORE & ASSOCIATES
The Gore Medical Products Division has provided creative therapeutic solutions to complex medical problems for three decades. During that time, more than 25 million innovative Gore Medical Devices have been implanted, saving and improving the quality of lives worldwide. The extensive Gore Medical family of products includes vascular grafts, endovascular and interventional devices, surgical materials for hernia repair, soft tissue reconstruction, staple line reinforcement, and sutures for use in vascular, cardiac and general surgery. Gore was recently named one of the best companies to work for by Fortune magazine for the 11th consecutive year. For more information, visit http://www.goremedical.com.
Products listed may not be available in all markets pending regulatory clearance. CARMEDA® BioActive Surface (CBAS®) is trademark of Carmeda AB, a wholly owned subsidiary of W. L. Gore & Associates. GORE, PROPATEN, VIABAHN®, and designs are trademarks of W. L. Gore & Associates.
Contact:
Schwartz Communications, Inc. for Gore Courtney Smith, 781-684-0770 GoreMedical@schwartz-pr.com
Source: W. L. Gore & Associates
